Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: A systematic review

World Journal of Surgical Oncology

Volumn 14, Issue 1, 2016, Pages

  Yang, Shu ^a   Lin, Qi ^b   Lin, Wei ^c   Hu, Weilei ^d   Wang, Guosheng ^d  

^a No 202 Hospital of PLA   (China)

^b Integrated Traditional and Western Medicine Hospital of Taizhou   (China)

^c FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PLACEBO; ALPHA INTERFERON; ANTIVIRUS AGENT;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CHEMOEMBOLIZATION; DRUG EFFECT; DRUG EFFICACY; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B; LIVER NEOPLASMS; PATHOGENICITY; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS;

EID: 84975106790     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-016-0912-7     Document Type: Review

References (32)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76.
2. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19(1):3-23.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17.
4. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229(3):322-30.
5. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181-200.
6. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43.
7. Chen SJ, Zhao YX, Fang Y, Xu WZ, Ma YX, Song ZW, et al. Viral deletions among healthy young Chinese adults with occult hepatitis B virus infection. Virus Res. 2012;163(1):197-201.
8. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100(2):376-82.
9. Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. Acta Medica Okayama. 2005;59(5):217-24.
10. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132(7):458-65.
11. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255(1):8-17.
12. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245(6):831-42.
13. Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, et al. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. Journal Gastroenterol Hepatol. 2009;24(8):1437-44.
14. Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17(1):179-85.
15. Zuo CH, Xia M, Liu JS, Qiu XX, Lei X, Xu RC, et al. Transcatheter arterial chemoembolization combined with interferon-alpha is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pacific journal of cancer prevention: APJCP. 2015;16(1):245-51.
16. Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. J Gastroenterol Hepatol. 2011;9(7):617-23. e1.
17. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2011;9(1):64-70.
18. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796-800.
19. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007;252(2):157-70.
20. Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, et al. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2009;35(2):174-9.
21. Ibrahim S, Roychowdhury A, Hean TK. Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Am J Surg. 2007;194(1):17-22.
22. Marrero J. Current treatment approaches in HCC. Clin Adv Hematol Oncol. 2013;11 Suppl 5(4):15--8.
23. Zhang W, Song T, Zhang T, Wu Q, Kong D, Li Q, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2(6):1125-34.
24. Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol. 2003;18(6):630-7.
25. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, et al. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nature Immunol. 2013;14(8):793-803.
26. Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ, et al. Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer. 2012;11:31.
27. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potentia. Hepatol (Baltimore, Md). 2000;32(1):43-8.
28. Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY. Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =. Chinese J Hepatol. 2013;21(5):335-9.
29. Liaw YF. Hepatitis B, virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther. 2006;11(6):669-79.
30. Ormeci N. Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol. 2003;17(6):651-8.
31. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357(9251):196-7.
32. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine. 2006;33(3):121-8.